Controversy Surrounds Abortion Pill Decision and FDA Support

Pfizer CEO Albert Bourla signed a letter along with over 200 pharmaceutical company executives in support of the FDA's authority to regulate drugs after a federal judge in Texas suspended the agency's approval of the abortion pill mifepristone. The executives raised concerns that the ruling will set a precedent for diminishing the FDA's authority over drug approvals, which would create uncertainty for the entire industry. The dueling orders by two federal judges create a complicated legal standoff that could potentially escalate to the Supreme Court.